A comprehensive exploration of adverse reactions to lapatinib: a disproportionate analysis based on the FAERS database
Y Zhou, J Gong, X Deng, L Shen, A Ge… - Expert opinion on …, 2025 - Taylor & Francis
Background Lapatinib, an FDA-approved tyrosine kinase inhibitor, treats HER2+
advanced/metastatic breast cancer. This study comprehensively analyzed its adverse …
advanced/metastatic breast cancer. This study comprehensively analyzed its adverse …